



In response to the rise of *C. auris* and the continued challenge from COVID variants, CSGI-USA and TMG Health Technologies persistently supplies healthcare facilities with the best possible defense against virulent pathogens that can **spread by touch** – **the RDS-32a Rapid UVC Decontamination System**.

C. auris is extremely difficult to eliminate from an environment once identified and it is resistant to antifungal drugs and the standard day-to-day disinfectants. It spreads in hospitals and other care facilities through person-to-person contact, contaminating surfaces and shared medical equipment. **Reducing the potential for cross-contamination is CRITICAL to patient and employee safety.** The [Centers for Disease Control and Prevention](#) (CDC) have classified *Candida auris* (*C. auris*) as an urgent public threat due to its role in elevating mortality, its ability to persist in hospital environments, and the high possibility of developing pan-drug resistance.

Ultraviolet germicidal irradiation is one of the recommended solutions that has proven successful in deactivating *C. auris* in addition to preventing its spread. The **RDS-32a** Rapid UVC Decontamination System from TMG Health Technologies is a proven solution against *C. auris*, *C. diff*, MRSA, the COVID variants and other major pathogens in its capacity to disinfect health electronics, communication devices, patient tools and packaged patient supplies in a single, 30 second cycle.

The RDS Can Deactivate *C. auris* In Just 30 Seconds

Independent lab studies have shown that one of the best defenses in the deactivation of *C. auris* is an ultraviolet dosage ranging from 0.108 to 0.176 cm²/mJ. The **RDS-32a** cabinets deliver a proven germicidal dosage that is considerably higher than the documented dosage of [103-192 mJ/cm²] to achieve high-level disinfection efficacy in only 30 seconds. Visit www.CSGIUSA.com for more information or to schedule a demonstration.

The RDS-32a is the top choice for continued UVC disinfection of shared equipment with long-term deployments within the MAYO Clinic, Providence Health, Veterans Administration Hospitals and Clinics, the Department of Defense, and the Department of Commerce.

The RDS-32a advantages include:

- Up to 6 Log₁₀ Efficacy or 99.9999%
- Patented M²D Technology Confirms Efficacy.
- 3.5 X's Larger Capacity to Disinfect 1000s Devices
- 10X's Longer Lamp Lifecycle
- No Preventative Maintenance Costs
- Disinfects both Wired & Wireless Devices
- Deployed as Fixed & Mobile Applications
- Battery Power Option
- Compliant: **Made in America Act**
- Three-Year Factory Warranty, Standard



UL, FCC, EPA Registered, Meets FDA Guidelines 2020, ISO9001:2015

The RDS-32a is available for immediate delivery.

To learn more, please contact CSGI at 888-631-0054 or by email at CustomerSupport@CSGIusa.com

• • • • •